Option Care Health reported a mixed first quarter, with management citing operational headwinds in its chronic therapy segment and a challenging reset in patient census resulting from benefit reverification and changes in insurance plan designs. CEO John Rademacher characterized the quarter as “mixed,” noting that while acute therapy performance was strong, revenue growth fell below expectations due to a higher volume of patient reauthorizations and unfavorable shifts in therapy mix. Management acknowledged that these dynamics led to an “unfavorable drop in census” and stated that the process of rebuilding would take time, reflecting a cautious outlook after the quarter’s underperformance.
Is now the time to buy OPCH? Find out in our full research report (it’s free for active Edge members).
Option Care Health (OPCH) Q1 CY2026 Highlights:
- Revenue: $1.35 billion vs analyst estimates of $1.40 billion (1.3% year-on-year growth, 3.3% miss)
- Adjusted EPS: $0.40 vs analyst estimates of $0.37 (8.1% beat)
- Adjusted EBITDA: $104.8 million vs analyst estimates of $103 million (7.8% margin, 1.7% beat)
- The company dropped its revenue guidance for the full year to $5.73 billion at the midpoint from $5.9 billion, a 3% decrease
- Management reiterated its full-year Adjusted EPS guidance of $1.87 at the midpoint
- EBITDA guidance for the full year is $492.5 million at the midpoint, in line with analyst expectations
- Operating Margin: 5.4%, in line with the same quarter last year
- Market Capitalization: $3.21 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Option Care Health’s Q1 Earnings Call
-
Lisa Gill (JPMorgan) asked about the drivers behind the increased gross profit headwind in the chronic segment. CFO Meenal Sethna explained it was primarily due to lower patient census and less favorable therapy mix, noting the challenge of rebuilding lost patient volumes.
-
Pito Chickering (Deutsche Bank) questioned the company’s ability to achieve sequential growth in EBITDA given the significant ramp required in the back half of the year. CEO John Rademacher pointed to strong acute segment performance and ongoing cost containment as key to the guidance.
-
David MacDonald (Truist) inquired about conversion rates and competitive factors affecting patient intake. Rademacher acknowledged some loss to competitors and higher administrative standards, but expects operational investments to support recovery.
-
Brian Tanquilut (Jefferies) pressed for clarity on market share loss and how management could build investor confidence in census recovery. Rademacher confirmed patient losses to competitors and self-administration, but expressed confidence in the reset baseline for future growth.
-
Joanna Gajuk (Bank of America) asked whether therapy mix changes were limited to Stelara or extended to other drugs. Management clarified the majority of impact was from Stelara patient transitions, with multiple alternative therapies in the mix.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will be watching (1) the pace of patient census recovery in chronic therapies, (2) sustained outperformance and margin contribution from acute therapy services, and (3) the effectiveness of commercial and operational investments in driving new patient referrals and conversions. Progress in payer and pharma partnerships, as well as execution on specialty product launches, will be additional indicators of momentum.
Option Care Health currently trades at $20.39, down from $26.87 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
